CA-AEVA,-INC.
Aeva, a leader in next generation sensing and perception systems, and ZF, a top global automotive Tier-1 supplier, are partnering to bring the world’s first Frequency Modulated Continuous Wave (FMCW) LiDAR to the automotive market. The partnership — Aeva's expertise in FMCW LiDAR technology combined with ZF's experience in industrialization of automotive grade sensors — represents a key commitment to accelerate mass production of safe and scalable 4D LiDAR technology for autonomous driving applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005368/en/
“From early on we have believed in building an ecosystem of the world’s most capable partners across the industry and this partnership is one part of that plan. ZF’s capability as one of the largest Tier-1s globally with expertise in automotive scale production of sensing systems is a key step to accelerating the introduction of safe and scalable autonomous vehicles,” said Soroush Salehian, Co-Founder of Aeva. “The industry is at the cusp of deploying the next generation of sensing to realize the adoption of highly automated and autonomous cars and we believe Aeva’s 4D LiDAR will be an indispensable part of this next chapter.”
About the Partnership
Aeva and ZF aim to bring the first automotive grade 4D LiDAR to market for autonomous driving applications. The partnership strengthens the parties’ collaboration by leveraging Aeva’s unique expertise in FMCW LiDAR and perception technology together with ZF’s expertise as a leading automotive supplier, autonomous systems provider, and market leader in smart cameras and the corresponding production know-how. The final system is targeted as a key solution for autonomous driving applications including established truck and OEM manufacturers as well as leading mobility as a service customers.
“LiDAR is a key technology for systems and sensing in the area of highly automated and autonomous driving. Aeva’s unique FMCW technology combines long range performance and direct velocity measurements, making it the right choice for autonomous driving applications. We have seen that different markets require different solutions. For L2+/L3 systems a package and cost optimized Lidar is crucial. For applications which feature L4 and further solutions, the focus lies on range and direct velocity measurement, as edge performance is key for the virtual driver software stack.
Aeva’s FMCW technology approach perfectly meets all the stringent requirements for autonomous operations in trucks and robo-service vehicles. We look forward to bring the world’s first FMCW LiDAR to an automotive grade level and scale production, where ZF can rely on a long-lasting production experience in optical sensors. ‘Automotive Grade’ will become a quality seal, necessary for a solid business model of all autonomous vehicle software stack providers,” said Torsten Gollewski, Executive Vice President Autonomous Mobility Solutions at ZF.
As part of the partnership, Aeva will be responsible for the FMCW LiDAR core sensing functionality, performance and algorithms and ZF will be responsible for industrialization of the automotive grade sensing system that meets all automotive requirements.
What makes Aeva’s 4D LiDAR unique?
Aeva’s FMCW technology is designed to meet the challenging performance and the manufacturability requirements for adoption of LiDAR in autonomous vehicles.
Unlike other LiDAR technologies, Aeva’s 4D LiDAR-on-chip uses a continuous laser beam to measure the change in frequency of the waveform as it reflects off of an object. This allows it to detect an object’s range and instant velocity simultaneously beyond 300 meters at high accuracy. Aeva’s 4D LiDAR is also completely free of interference from other sensors or sunlight and it operates at only fractions of the optical power typically required to achieve long range performance. All of which are critical hurdles that have previously slowed the broad adoption of automotive LiDAR.
Aeva’s technology also differs from other FMCW approaches in its unique ability to break the dependency between maximum range and points density. Aeva’s 4D LiDAR integrates multiple beams on a chip that is produced at silicon wafer scale. Each beam is uniquely capable of measuring multiple millions of points per second at maximum range providing unprecedented data fidelity and significantly enhancing the factor of safety for self-driving cars.
About Aeva
Aeva was founded in 2017 by Soroush Salehian, and Mina Rezk -- previously engineering leaders at Apple & Nikon. Headquartered in Mountain View, California, Aeva is building the next-generation of sensing and perception for autonomous vehicles that is safe, simple, and scalable. Aeva is backed by Volkswagen’s Porsche SE, Lux Capital and Canaan Partners, amongst others. For more information, visit www.aeva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005368/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
